1
|
Fang T, Liu L, Song D, Huang D. The role of MIF in periodontitis: A potential pathogenic driver, biomarker, and therapeutic target. Oral Dis 2024; 30:921-937. [PMID: 36883414 DOI: 10.1111/odi.14558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 02/08/2023] [Accepted: 03/01/2023] [Indexed: 03/09/2023]
Abstract
OBJECTIVE Periodontitis is an inflammatory disease that involves an imbalance in the oral microbiota, activation of inflammatory and immune responses, and alveolar bone destruction. Macrophage migration inhibitory factor (MIF) is a versatile cytokine involved in several pathological reactions, including inflammatory processes and bone destruction, both of which are characteristics of periodontitis. While the roles of MIF in cancer and other immune diseases have been extensively characterized, its role in periodontitis remains inconclusive. RESULTS In this review, we describe a comprehensive analysis of the potential roles of MIF in periodontitis from the perspective of immune response and bone regulation at the cellular and molecular levels. Moreover, we discuss its potential reliability as a novel diagnostic and therapeutic target for periodontitis. CONCLUSION This review can aid dental researchers and clinicians in understanding the current state of MIF-related pathogenesis, diagnosis, and treatment of periodontitis.
Collapse
Affiliation(s)
- Tongfeng Fang
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Liu Liu
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
- Department of Conservative Dentistry and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Dongzhe Song
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
- Department of Conservative Dentistry and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| | - Dingming Huang
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
- Department of Conservative Dentistry and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
| |
Collapse
|
2
|
Canalis E, Schilling L, Yu J, Denker E. NOTCH2 promotes osteoclast maturation and metabolism and modulates the transcriptome profile during osteoclastogenesis. J Biol Chem 2024; 300:105613. [PMID: 38159855 PMCID: PMC10837628 DOI: 10.1016/j.jbc.2023.105613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 12/11/2023] [Accepted: 12/22/2023] [Indexed: 01/03/2024] Open
Abstract
Notch signaling plays a key regulatory role in bone remodeling and NOTCH2 enhances osteoclastogenesis, an effect that is mostly mediated by its target gene Hes1. In the present study, we explored mechanisms responsible for the enhanced osteoclastogenesis in bone marrow-derived macrophages (BMM) from Notch2tm1.1Ecan, harboring a NOTCH2 gain-of-function mutation, and control mice. Notch2tm1.1Ecan mice are osteopenic and have enhanced osteoclastogenesis. Bulk RNA-Seq and gene set enrichment analysis of Notch2tm1.1Ecan BMMs cultured in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator of NF-κB ligand revealed enrichment of genes associated with enhanced cell metabolism, aerobic respiration, and mitochondrial function, all associated with osteoclastogenesis. These pathways were not enhanced in the context of a Hes1 inactivation. Analysis of single cell RNA-Seq data of pooled control and Notch2tm1.1Ecan BMMs treated with M-CSF or M-CSF and receptor activator of NF-κB ligand for 3 days identified 11 well-defined cellular clusters. Pseudotime trajectory analysis indicated a trajectory of clusters expressing genes associated with osteoclast progenitors, osteoclast precursors, and mature cells. There were an increased number of cells expressing gene markers associated with the osteoclast and with an unknown, albeit related, cluster in Notch2tm1.1Ecan than in control BMMs as well as enhanced expression of genes associated with osteoclast progenitors and precursors in Notch2tm1.1Ecan cells. In conclusion, BMM cultures display cellular heterogeneity, and NOTCH2 enhances osteoclastogenesis, increases mitochondrial and metabolic activity of osteoclasts, and affects cell cluster allocation in BMMs.
Collapse
Affiliation(s)
- Ernesto Canalis
- Department of Orthopaedic Surgery, UConn Health, Farmington, Connecticut, USA; Department of Medicine, UConn Health, Farmington, Connecticut, USA; UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA.
| | - Lauren Schilling
- UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA
| | - Jungeun Yu
- Department of Orthopaedic Surgery, UConn Health, Farmington, Connecticut, USA; UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA
| | - Emily Denker
- UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA
| |
Collapse
|
3
|
Zeng J, Jiang X, Jiang M, Cao Y, Jiang Y. Bioinformatics analysis of hub genes as osteoarthritis prognostic biomarkers. Sci Rep 2023; 13:22894. [PMID: 38129488 PMCID: PMC10739719 DOI: 10.1038/s41598-023-48446-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 11/27/2023] [Indexed: 12/23/2023] Open
Abstract
Osteoarthritis (OA) is a progressive cartilage degradation disease, concomitant with synovitis, osteophyte formation, and subchondral bone sclerosis. Over 37% of the elderly population is affected by OA, and the number of cases is increasing as the global population ages. Therefore, the objective of this study was to identify and analyze the hub genes of OA combining with comprehensive bioinformatics analysis tools to provide theoretical basis in further OA effective therapies. Two sample sets of GSE46750 contained 12 pairs OA synovial membrane and normal samples harvested from patients as well as GSE98918 including 12 OA and non-OA patients were downloaded from the Gene Expression Omnibus database (GEO) database. Differentially expressed genes (DEGs) were identified using Gene Expression Omnibus 2R (GEO2R), followed by functional enrichment analysis, protein-protein interaction networks construction. The hub genes were identified and evaluated. An OA rat model was constructed, hematoxylin and eosin staining, safranin O/fast green staining, cytokines concentrations of serum were used to verify the model. The hub genes expression level in the knee OA samples were verified using RT-qPCR. The top 20 significantly up-regulated and down-regulated DEGs were screened out from the two datasets, respectively. The top 18 GO terms and 10 KEGG pathways were enriched. Eight hub genes were identified, namely MS4A6A, C1QB, C1QC, CD74, CSF1R, HLA-DPA1, HLA-DRA and ITGB2. Among them, the hub genes were all up-regulated in in vivo OA rat model, compared with healthy controls. The eight hub genes identified (MS4A6A, C1QB, C1QC, CD74, CSF1R, HLA-DPA1, HLA-DRA and ITGB2) were shown to be associated with OA. These genes can serve as disease markers to discriminate OA patients from healthy controls.
Collapse
Affiliation(s)
- Junfeng Zeng
- Department of Orthopedics, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Donghu District, Nanchang City, Jiangxi Province, 330000, People's Republic of China
| | - Xinhao Jiang
- Department of Orthopedics, Yugan County Hospital, No. 1, Mianshan Avenue, Yugan County, Shangrao City, Jiangxi Province, 335100, People's Republic of China
| | - Mo Jiang
- Department of Orthopedics 10th, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, No. 445, Bayi Avenue, Donghu District, Nanchang City, Jiangxi Province, 330000, People's Republic of China
| | - Yuexia Cao
- Department of Orthopedics, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Donghu District, Nanchang City, Jiangxi Province, 330000, People's Republic of China
| | - Yi Jiang
- Department of Orthopedics, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwaizheng Street, Donghu District, Nanchang City, Jiangxi Province, 330000, People's Republic of China.
| |
Collapse
|
4
|
Zhang Y, Zheng L, Fang J, Ni K, Hu X, Ye L, Lai H, Yang T, Chen Z, He D. Macrophage migration inhibitory factor (MIF) promotes intervertebral disc degeneration through the NF-κB pathway, and the MIF inhibitor CPSI-1306 alleviates intervertebral disc degeneration in a mouse model. FASEB J 2023; 37:e23303. [PMID: 37983963 DOI: 10.1096/fj.202301441r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Revised: 10/07/2023] [Accepted: 10/26/2023] [Indexed: 11/22/2023]
Abstract
Lumbar intervertebral disc degeneration(IDD) is a prevalent inflammatory disease caused by many proinflammatory factors, such as TNF and IL-1β. Migration inhibitory factor (MIF) is an upstream inflammatory factor widely expressed in vivo that is associated with a variety of inflammatory diseases or malignant tumors and has potential therapeutic value in many diseases. We explored the role of MIF in intervertebral disc degeneration by regulating the content of exogenous MIF or the expression of MIF in cells. Upon inducing degeneration of nucleus pulposus (NP) cells with IL-1β, we found that the increase in intracellular and exogenous MIF promoted the catabolism induced by proinflammatory factors in NP cells, while silencing of the MIF gene alleviated the degeneration to some extent. In a mouse model, the intervertebral disc degeneration of MIF-KO mice was significantly less than that of wild-type mice. To explore the treatment of intervertebral disc degeneration, we selected the small-molecular MIF inhibitor CPSI-1306. CPSI-1306 had a therapeutic effect on intervertebral disc degeneration in the mouse model. In summary, we believe that MIF plays an important role in intervertebral disc degeneration and is a potential therapeutic target for the treatment of intervertebral disc degeneration.
Collapse
Affiliation(s)
- Yejin Zhang
- Department of Orthopaedic Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
| | - Lin Zheng
- Department of Orthopaedics, The Second Affiliated Hospital of Wenzhou Medical College, Wenzhou, China
| | - Jiawei Fang
- Department of Orthopaedic Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
| | - Kainan Ni
- Department of Orthopaedics, The First People's Hospital of Fuyang, Hangzhou, China
| | - Xingyu Hu
- Department of Orthopaedic Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
| | - Lin Ye
- Department of Orthopaedic Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
| | - Hehuan Lai
- Department of Orthopaedic Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
| | - Tao Yang
- Department of Orthopaedic Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
| | - Zhenzhong Chen
- Department of Orthopaedic Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
| | - Dengwei He
- Department of Orthopaedic Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China
| |
Collapse
|
5
|
He J, Zheng L, Li X, Huang F, Hu S, Chen L, Jiang M, Lin X, Jiang H, Zeng Y, Ye T, Lin D, Liu Q, Xu J, Chen K. Obacunone targets macrophage migration inhibitory factor (MIF) to impede osteoclastogenesis and alleviate ovariectomy-induced bone loss. J Adv Res 2023; 53:235-248. [PMID: 36657717 PMCID: PMC10658311 DOI: 10.1016/j.jare.2023.01.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Revised: 09/21/2022] [Accepted: 01/06/2023] [Indexed: 01/18/2023] Open
Abstract
INTRODUCTION Osteoporosis is the most common bone disorder where the hyperactive osteoclasts represent the leading role during the pathogenesis. Targeting hyperactive osteoclasts is currently the primary therapeutic strategy. However, concerns about the long-term efficacy and side effects of current frontline treatments persist. Alternative therapeutic agents are still needed. OBJECTIVES Obacunone (OB) is a small molecule with a broad spectrum of biological activities, particularly antioxidant and anti-inflammatory effects. This study aims to examine OB's therapeutic potential on osteoporosis and explore the rudimentary mechanisms. METHODS Osteoclast formation and osteoclastic resorption assays were carried out to examine OB's inhibitory effects in vitro, followed by the in-vivo studies of OB's therapeutic effects on ovariectomy-induced osteoporotic preclinical model. To further study the underlying mechanisms, mRNA sequencing and analysis were used to investigate the changes of downstream pathways. The molecular targets of OB were predicted, and in-silico docking analysis was performed. Ligand-target binding was verified by surface plasmon resonance (SPR) assay and Western Blotting assay. RESULTS The results indicated that OB suppressed the formation of osteoclast and its resorptive function in vitro. Mechanistically, OB interacts with macrophage migration inhibitory factor (MIF) which attenuates receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL)-induced signaling pathways, including reactive oxygen species (ROS), NF-κB pathway, and mitogen-activated protein kinases (MAPKs). These effects eventually caused the diminished expression level of the master transcriptional factor of osteoclastogenesis, nuclear factor of activated T cells 1 (NFATc1), and its downstream osteoclast-specific proteins. Furthermore, our data revealed that OB alleviated estrogen deficiency-induced osteoporosis by targeting MIF and thus inhibiting hyperactive osteoclasts in vivo. CONCLUSION These results together implicated that OB may represent as a therapeutic candidate for bone disorders caused by osteoclasts, such as osteoporosis.
Collapse
Affiliation(s)
- Jianbo He
- Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou 510632, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China; School of Biomedical Sciences, The University of Western Australia, Perth 6009, Australia
| | - Lin Zheng
- Department of Orthopedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou 310000, China
| | - Xiaojuan Li
- Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou 510632, China
| | - Furong Huang
- Department of Orthopedics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Sitao Hu
- Department of Orthopedics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Lei Chen
- Department of Orthopedics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Manya Jiang
- Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility, Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou 510632, China
| | - Xianfeng Lin
- Department of Orthopedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou 310000, China
| | - Haibo Jiang
- School of Molecular Sciences, The University of Western Australia, Perth 6009, Australia
| | - Yifan Zeng
- Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Tianshen Ye
- Department of Acupuncture, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Dingkun Lin
- State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China
| | - Qian Liu
- Guangxi Key Laboratory of Regenerative Medicine, Orthopedic Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
| | - Jiake Xu
- School of Biomedical Sciences, The University of Western Australia, Perth 6009, Australia.
| | - Kai Chen
- Department of Orthopedics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China; School of Molecular Sciences, The University of Western Australia, Perth 6009, Australia.
| |
Collapse
|
6
|
Wu B, Nakamura A. Deep Insight into the Role of MIF in Spondyloarthritis. Curr Rheumatol Rep 2022; 24:269-278. [PMID: 35809213 DOI: 10.1007/s11926-022-01081-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/05/2022] [Indexed: 11/28/2022]
Abstract
PURPOSE OF REVIEW Pathological roles of macrophage migration inhibitory factor (MIF) have recently been demonstrated in spondyloarthritis (SpA) preclinical models, identifying MIF as a new treatment target for SpA. However, the specific contribution of MIF and therapeutic potential of MIF-targeted therapies to various tissue types affected by SpA are not well delineated. RECENT FINDINGS MIF and its cognate receptor CD74 are extensively involved in the pathogenesis of SpA including inflammation in the spine, joint, eyes, skin, and gut. The majority of the current evidence has consistently shown that MIF drives the inflammation in these distinct anatomical sites. In preclinical models, genetic deletion or blockade of MIF reduces the severity of inflammation. Although MIF is generally an upstream cytokine which regulates downstream effector cytokines, MIF also intensifies type 3 immunity by promoting helper T 17 (Th17) plasticity. MIF- or CD74-targeted therapies have also reported to be well tolerated in clinical trials for other diseases. Recent findings suggest that MIF-CD74 axis is a new therapeutic target for SpA to improve various clinical features. Clinical trials for MIF- or CD74-targeted therapies for SpA patients are warranted.
Collapse
Affiliation(s)
- Brian Wu
- Schroeder Arthritis Institute, University Health Network, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Canada.,Krembil Research Institute, University Health Network, Toronto, ON, Canada.,Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada
| | - Akihiro Nakamura
- Schroeder Arthritis Institute, University Health Network, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Canada. .,Krembil Research Institute, University Health Network, Toronto, ON, Canada. .,Division of Rheumatology, Toronto Western Hospital, University Health Network, Toronto, ON, Canada. .,Institute of Medical Science, Temerty Faculty of Medicine of Medicine, University of Toronto, Toronto, ON, Canada.
| |
Collapse
|
7
|
Peng F, Yan S, Liu H, Liu Z, Jiang F, Cao P, Fu R. Roles of LINC01473 and CD74 in osteoblasts in multiple myeloma bone disease. J Investig Med 2022; 70:1301-1307. [PMID: 35145037 PMCID: PMC9240337 DOI: 10.1136/jim-2021-002192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/06/2022] [Indexed: 11/22/2022]
Abstract
The suppression of osteoblast (OB) activity is partially responsible for multiple myeloma (MM) bone disease. Long non-coding RNAs (lncRNAs) play a vital role in bone formation and resorption. However, their functions in OBs from patients with MM have rarely been reported. Through high-throughput sequencing of OBs from patients with MM and healthy controls, we identified several lncRNAs and messenger RNAs (mRNAs) with different expression profile and validated them using quantitative real-time PCR. In total, 22 upregulated and 21 downregulated lncRNAs were found in OBs from patients with MM. Moreover, 18 upregulated protein-coding mRNAs were identified. The expression levels of LINC01473 and its associated co-expression mRNA, CD74, were higher in patients with MM than in healthy controls (p=0.047 and p=0.016, respectively). LINC01473 expression demonstrated a negative correlation with serum interleukin-2 and tumor necrosis factor α levels, whereas the expression of mRNA CD74 was positively associated with serum lactic dehydrogenase in patients with MM. Aberrant expression of lncRNAs and mRNAs was observed in OBs from patients with MM. This study identifies new promising targets for further research on imbalanced bone formation and resorption and MM immune escape.
Collapse
Affiliation(s)
- Fengping Peng
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| | - Siyang Yan
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| | - Hui Liu
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| | - Zhaoyun Liu
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| | - Fengjuan Jiang
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| | - Panpan Cao
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| | - Rong Fu
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| |
Collapse
|
8
|
Baranowsky A, Jahn D, Jiang S, Yorgan T, Ludewig P, Appelt J, Albrecht KK, Otto E, Knapstein P, Donat A, Winneberger J, Rosenthal L, Köhli P, Erdmann C, Fuchs M, Frosch KH, Tsitsilonis S, Amling M, Schinke T, Keller J. Procalcitonin is expressed in osteoblasts and limits bone resorption through inhibition of macrophage migration during intermittent PTH treatment. Bone Res 2022; 10:9. [PMID: 35087025 PMCID: PMC8795393 DOI: 10.1038/s41413-021-00172-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 07/01/2021] [Accepted: 08/10/2021] [Indexed: 12/13/2022] Open
Abstract
Intermittent injections of parathyroid hormone (iPTH) are applied clinically to stimulate bone formation by osteoblasts, although continuous elevation of parathyroid hormone (PTH) primarily results in increased bone resorption. Here, we identified Calca, encoding the sepsis biomarker procalcitonin (ProCT), as a novel target gene of PTH in murine osteoblasts that inhibits osteoclast formation. During iPTH treatment, mice lacking ProCT develop increased bone resorption with excessive osteoclast formation in both the long bones and axial skeleton. Mechanistically, ProCT inhibits the expression of key mediators involved in the recruitment of macrophages, representing osteoclast precursors. Accordingly, ProCT arrests macrophage migration and causes inhibition of early but not late osteoclastogenesis. In conclusion, our results reveal a potential role of osteoblast-derived ProCT in the bone microenvironment that is required to limit bone resorption during iPTH.
Collapse
Affiliation(s)
- Anke Baranowsky
- Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany.,Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Denise Jahn
- Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany.,Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany
| | - Shan Jiang
- Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Timur Yorgan
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Peter Ludewig
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany
| | - Jessika Appelt
- Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany.,Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany
| | - Kai K Albrecht
- Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany
| | - Ellen Otto
- Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany.,Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany
| | - Paul Knapstein
- Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Antonia Donat
- Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Jack Winneberger
- Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany
| | - Lana Rosenthal
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Paul Köhli
- Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany.,Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany
| | - Cordula Erdmann
- Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Melanie Fuchs
- Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany.,Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany
| | - Karl-Heinz Frosch
- Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Serafeim Tsitsilonis
- Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany.,Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité-Universitätsmedizin Berlin, Berlin, 13353, Germany
| | - Michael Amling
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Thorsten Schinke
- Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany
| | - Johannes Keller
- Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany. .,Berlin Institute of Health, Berlin, 10178, Germany.
| |
Collapse
|
9
|
Schwann Cells Accelerate Osteogenesis via the Mif/CD74/FOXO1 Signaling Pathway In Vitro. Stem Cells Int 2022; 2022:4363632. [PMID: 35069747 PMCID: PMC8776480 DOI: 10.1155/2022/4363632] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 11/13/2021] [Accepted: 12/21/2021] [Indexed: 12/24/2022] Open
Abstract
Schwann cells have been found to promote osteogenesis by an unclear molecular mechanism. To better understand how Schwann cells accelerate osteogenesis, RNA-Seq and LC-MS/MS were utilized to explore the transcriptomic and metabolic response of MC3T3-E1 to Schwann cells. Osteogenic differentiation was determined by ALP staining. Lentiviruses were constructed to alter the expression of Mif (macrophage migration inhibitory factor) in Schwann cells. Western blot (WB) analysis was employed to detect the protein expression. The results of this study show that Mif is essential for Schwann cells to promote osteogenesis, and its downstream CD74/FOXO1 is also involved in the promotion of Schwann cells on osteogenesis. Further, Schwann cells regulate amino acid metabolism and lipid metabolism in preosteoblasts. These findings unveil the mechanism for Schwann cells to promote osteogenesis where Mif is a key factor.
Collapse
|
10
|
Deng M, Tan J, Dai Q, Luo F, Xu J. Macrophage-Mediated Bone Formation in Scaffolds Modified With MSC-Derived Extracellular Matrix Is Dependent on the Migration Inhibitory Factor Signaling Pathway. Front Cell Dev Biol 2021; 9:714011. [PMID: 34621738 PMCID: PMC8490662 DOI: 10.3389/fcell.2021.714011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 08/09/2021] [Indexed: 12/25/2022] Open
Abstract
The positive role of macrophages in the osteogenesis of mesenchymal stem cells (MSCs) has been a recent research focus. On the other hand, MSCs could carefully regulate the paracrine molecules derived from macrophages. Human umbilical cord mesenchymal stem cells (hucMSCs) can reduce the secretion of inflammatory factors from macrophages to improve injury healing. hucMSC-derived extracellular matrix (hucMSC-ECM) has the similar effect to hucMSCs, which could combat the inflammatory response of macrophages. Additionally, MSC-derived extracellular matrix also enhanced bone regeneration by inhibiting osteoclastic differentiation of monocyte/macrophage lineage. However, whether hucMSC-ECM could improve bone formation by guiding macrophage-induced osteogenic differentiation of MSCs is unknown. Here, we present decalcified bone scaffolds modified by hucMSC-derived extracellular matrix (DBM-ECM), which maintained multiple soluble cytokines from hucMSCs, including macrophage migration inhibitory factor (MIF). Compared with DBM, the DBM-ECM scaffolds induced bone formation in an improved heterotopic ossification model of severe combined immunodeficiency (SCID) mice in a macrophage-dependent manner. Macrophages cocultured with DBM-ECM expressed four osteoinductive cytokines (BMP2, FGF2, TGFβ3 and OSM), which were screened out by RNA sequencing and measured by qPCR and western blot. The conditioned medium from macrophages cocultured with DBM-ECM improved the osteogenic differentiation of hBMSCs. Furthermore, DBM-ECM activated CD74/CD44 (the typical MIF receptors) signal transduction in macrophages, including phosphorylation of P38 and dephosphorylation of c-jun. On the other side, the inhibitory effects of the DBM-ECM scaffolds with a deficient of MIF on osteogenesis in vitro and in vivo revealed that macrophage-mediated osteogenesis depended on MIF/CD74 signal transduction. The results of this study indicate that the coordinated crosstalk of macrophages and MSCs plays a key role on bone regeneration, with an emphasis on hucMSC-ECM constructing a macrophage-derived osteoinductive microenvironment.
Collapse
Affiliation(s)
- Moyuan Deng
- Department of Orthopaedics, Southwest Hospital, Army Medical University, Chongqing, China
| | - Jiulin Tan
- Department of Orthopaedics, Southwest Hospital, Army Medical University, Chongqing, China
| | - Qijie Dai
- Department of Orthopaedics, Southwest Hospital, Army Medical University, Chongqing, China
| | - Fei Luo
- Department of Orthopaedics, Southwest Hospital, Army Medical University, Chongqing, China
| | - Jianzhong Xu
- Department of Orthopaedics, Southwest Hospital, Army Medical University, Chongqing, China
| |
Collapse
|
11
|
Wirtz TH, Saal A, Bergmann I, Fischer P, Heinrichs D, Brandt EF, Koenen MT, Djudjaj S, Schneider KM, Boor P, Bucala R, Weiskirchen R, Bernhagen J, Trautwein C, Berres ML. Macrophage migration inhibitory factor exerts pro-proliferative and anti-apoptotic effects via CD74 in murine hepatocellular carcinoma. Br J Pharmacol 2021; 178:4452-4467. [PMID: 34250589 DOI: 10.1111/bph.15622] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 06/23/2021] [Accepted: 06/25/2021] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND AND PURPOSE Macrophage migration inhibitory factor (MIF) is an inflammatory and chemokine-like protein expressed in different inflammatory diseases as well as solid tumours. CD74-as the cognate MIF receptor-was identified as an important target of MIF. We here analysed the role of MIF and CD74 in the progression of hepatocellular carcinoma (HCC) in vitro and in vivo. EXPERIMENTAL APPROACH Multilocular HCC was induced using the diethylnitrosamine/carbon tetrachloride (DEN/CCl4 ) model in hepatocyte-specific Mif knockout (Mif Δhep ), Cd74-deficient, and control mice. Tumour burden was compared between the genotypes. MIF, CD74 and Ki67 expression were investigated in tumour and surrounding tissue. In vitro, the effects of the MIF/CD74 axis on the proliferative and apoptotic behaviour of hepatoma cells and respective signalling pathways were assessed after treatment with MIF and anti-CD74 antibodies. KEY RESULTS DEN/CCl4 treatment of Mif Δhep mice resulted in reduced tumour burden and diminished proliferation capacity within tumour tissue. In vitro, MIF stimulated proliferation of Hepa 1-6 and HepG2 cells, inhibited therapy-induced cell death and induced ERK activation. The investigated effects could be reversed using a neutralizing anti-CD74 antibody, and Cd74-/- mice developed fewer tumours associated with decreased proliferation rates. CONCLUSION AND IMPLICATIONS We identified a pro-tumorigenic role of MIF during proliferation and therapy-induced apoptosis of HCC cells. These effects were mediated via the MIF cognate receptor CD74. Thus, inhibition of the MIF/CD74 axis could represent a promising target with regard to new pharmacological therapies aimed at HCC.
Collapse
Affiliation(s)
- Theresa H Wirtz
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Alena Saal
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Irina Bergmann
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Petra Fischer
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Daniel Heinrichs
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Elisa F Brandt
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Maria T Koenen
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Sonja Djudjaj
- Institute of Pathology, RWTH Aachen University, Aachen, Germany
| | - Kai M Schneider
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Peter Boor
- Institute of Pathology, RWTH Aachen University, Aachen, Germany.,Department of Nephrology and Immunology, RWTH Aachen University, Aachen, Germany
| | - Richard Bucala
- Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Ralf Weiskirchen
- Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital RWTH Aachen, Aachen, Germany
| | - Jürgen Bernhagen
- Division of Vascular Biology, Institute for Stroke and Dementia Research (ISD), Ludwig Maximilian-University (LMU) and LMU University Hospital, Munich, Germany.,Munich Cluster for Systems Neurology (EXC 2145 SyNergy), Munich, Germany
| | - Christian Trautwein
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| | - Marie-Luise Berres
- Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany
| |
Collapse
|
12
|
Ai T, Hao L, Shang L, Wang L, Li B, Li J. Konjac Oligosaccharides Modulate the Gut Environment and Promote Bone Health in Calcium-Deficient Mice. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2021; 69:4412-4422. [PMID: 33832226 DOI: 10.1021/acs.jafc.0c07839] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
This study aimed to investigate the beneficial effect of konjac oligosaccharides (KOS) on bone health in calcium-deficient mice. During the experimental period, low-calcium diet-fed mice were administered with calcium chloride to simulate daily calcium supplementation. Meanwhile, different levels of KOS intervened by adding them into the diet. After 8 weeks, the calcium balance status, bone mass parameters, and gut environment modulation were evaluated. The results showed that dietary KOS intervention alleviated the negative calcium balance, significantly promoted the trabecular number and cortical thickness, and remarkably enhanced the skeletal mechanical strength. Moreover, Pearson's correlation analysis among significantly changed gut microbiota, gut metabolites, and relevant physiological indexes showed that the microbial genera of Lactobacillus, Bifidobacterium, Mucispirillum, Alistipes, and unidentified Clostridia and gut metabolites of kynurenine and testosterone were significantly associated with increased bone mass. These findings provided a new insight into the effect of prebiotics on bone health.
Collapse
Affiliation(s)
- Tingyang Ai
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China
- Key Laboratory of Environment Correlative Dietology, Huazhong Agricultural University, Ministry of Education, Wuhan 430070, China
| | - Lulu Hao
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China
- Key Laboratory of Environment Correlative Dietology, Huazhong Agricultural University, Ministry of Education, Wuhan 430070, China
| | - Longchen Shang
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China
- Key Laboratory of Environment Correlative Dietology, Huazhong Agricultural University, Ministry of Education, Wuhan 430070, China
| | - Ling Wang
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China
- Key Laboratory of Environment Correlative Dietology, Huazhong Agricultural University, Ministry of Education, Wuhan 430070, China
| | - Bin Li
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China
- Key Laboratory of Environment Correlative Dietology, Huazhong Agricultural University, Ministry of Education, Wuhan 430070, China
| | - Jing Li
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070, China
- Key Laboratory of Environment Correlative Dietology, Huazhong Agricultural University, Ministry of Education, Wuhan 430070, China
| |
Collapse
|
13
|
Becker-Herman S, Rozenberg M, Hillel-Karniel C, Gil-Yarom N, Kramer MP, Barak A, Sever L, David K, Radomir L, Lewinsky H, Levi M, Friedlander G, Bucala R, Peled A, Shachar I. CD74 is a regulator of hematopoietic stem cell maintenance. PLoS Biol 2021; 19:e3001121. [PMID: 33661886 PMCID: PMC7963458 DOI: 10.1371/journal.pbio.3001121] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 03/16/2021] [Accepted: 01/29/2021] [Indexed: 11/17/2022] Open
Abstract
Hematopoietic stem and progenitor cells (HSPCs) are a small population of undifferentiated cells that have the capacity for self-renewal and differentiate into all blood cell lineages. These cells are the most useful cells for clinical transplantations and for regenerative medicine. So far, it has not been possible to expand adult hematopoietic stem cells (HSCs) without losing their self-renewal properties. CD74 is a cell surface receptor for the cytokine macrophage migration inhibitory factor (MIF), and its mRNA is known to be expressed in HSCs. Here, we demonstrate that mice lacking CD74 exhibit an accumulation of HSCs in the bone marrow (BM) due to their increased potential to repopulate and compete for BM niches. Our results suggest that CD74 regulates the maintenance of the HSCs and CD18 expression. Its absence leads to induced survival of these cells and accumulation of quiescent and proliferating cells. Furthermore, in in vitro experiments, blocking of CD74 elevated the numbers of HSPCs. Thus, we suggest that blocking CD74 could lead to improved clinical insight into BM transplant protocols, enabling improved engraftment. Hematopoietic stem and progenitor cells (HSPCs) can self-renew and differentiate into all blood cell lineages, making them useful for clinical transplantations and regenerative medicine. This study shows that blocking the MIF receptor CD74 increases the accumulation of HSPCs and could improve the efficacy of bone marrow transplantation protocols.
Collapse
Affiliation(s)
| | - Milena Rozenberg
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | | | - Naama Gil-Yarom
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Mattias P Kramer
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Avital Barak
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Lital Sever
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Keren David
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Lihi Radomir
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Hadas Lewinsky
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Michal Levi
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| | - Gilgi Friedlander
- Ilana and Pascal Mantoux Institute for Bioinformatics and Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel
| | - Richard Bucala
- Internal Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America
| | - Amnon Peled
- Hadassah Hebrew University Hospital, Goldyne Savad Institute of Gene Therapy, Jerusalem, Israel
| | - Idit Shachar
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
| |
Collapse
|
14
|
Cheng WL, Kao YH, Chen YC, Lin YK, Chen SA, Chen YJ. Macrophage migration inhibitory factor increases atrial arrhythmogenesis through CD74 signaling. Transl Res 2020; 216:43-56. [PMID: 31669150 DOI: 10.1016/j.trsl.2019.10.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Revised: 09/04/2019] [Accepted: 10/02/2019] [Indexed: 01/23/2023]
Abstract
Macrophage migration inhibitory factor (MIF), a pleiotropic inflammatory cytokine, is highly expressed in patients with atrial fibrillation (AF). CD74 (major histocompatibility complex, class II invariant chain) is the main receptor for MIF. However, the role of the MIF/CD74 axis in atrial arrhythmogenesis is unclear. In this study, we investigated the effects of MIF/CD74 signaling on atrial electrophysiological characteristics and determined its underlying mechanisms. Confocal fluorescence microscopy, patch clamp, and western blot analysis were used to study calcium homeostasis, ionic currents, and calcium-related signaling in MIF-treated HL-1 atrial cardiomyocytes with or without anti-CD74 neutralized antibodies treatment. Furthermore, electrocardiographic telemetry recording and echocardiography were obtained from mice treated with MIF. Compared with controls, MIF-treated HL-1 myocytes had increased calcium transients, sarcoplasmic reticulum (SR) calcium content, Na+/Ca2+ exchanger (NCX) efflux rate, calcium leak, transient outward potassium current, and ultra-rapid delayed rectifier potassium current. Furthermore, MIF could induce expression of SR Ca2+ATPase, NCX, phosphorylation of ryanodine receptor 2 (RyR2), and activation of calcium/calmodulin kinase II (CaMKII) when compared with control cells. MIF-mediated electrical dysregulation and CaMKII-RyR2 signaling activation were attenuated through blocking of CD74. Moreover, MIF-injected mice had lesser left atrium fractional shortening, greater atrial fibrosis, and atrial ectopic beats than control (nonspecific immunoglobulin treated) or MIF combined with anti-CD74 neutralized antibody-treated mice. Consequently, our study on MIF/CD74 signaling has pointed out a new potential therapeutic intervention of AF patients with MIF elevation.
Collapse
Affiliation(s)
- Wan-Li Cheng
- Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Yu-Hsun Kao
- Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Medical Education and Research, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| | - Yao-Chang Chen
- Department of Biomedical Engineering, National Defense Medical Center, Taipei, Taiwan
| | - Yung-Kuo Lin
- Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Division of Cardiovascular Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| | - Shih-Ann Chen
- Division of Cardiology and Cardiovascular Research Center, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Yi-Jen Chen
- Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Cardiovascular Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
| |
Collapse
|
15
|
Abstract
Cytokines and hematopoietic growth factors have traditionally been thought of as regulators of the development and function of immune and blood cells. However, an ever-expanding number of these factors have been discovered to have major effects on bone cells and the development of the skeleton in health and disease (Table 1). In addition, several cytokines have been directly linked to the development of osteoporosis in both animal models and in patients. In order to understand the mechanisms regulating bone cells and how this may be dysregulated in disease states, it is necessary to appreciate the diverse effects that cytokines and inflammation have on osteoblasts, osteoclasts, and bone mass. This chapter provides a broad overview of this topic with extensive references so that, if desired, readers can access specific references to delve into individual topics in greater detail.
Collapse
Affiliation(s)
- Joseph Lorenzo
- Departments of Medicine and Orthopaedic Surgery, UConn Health, Farmington, CT, USA.
| |
Collapse
|
16
|
Tunneling nanotubes mediate intercellular communication between endothelial progenitor cells and osteoclast precursors. J Mol Histol 2019; 50:483-491. [PMID: 31463584 DOI: 10.1007/s10735-019-09842-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Accepted: 08/21/2019] [Indexed: 01/01/2023]
Abstract
Tunneling nanotube (TNT)-mediated cell communication play pivotal roles in a series of physiological and pathological processes in multicellular organism. This study was designed to investigate the existence of TNTs between EPCs and osteoclast precursors and evaluate their effects on the differentiation of osteoclast precursors. For these purposes, EPCs and osteoclast precursors (RAW264.7 cells) were stained with different fluorescent dyes before direct co-culture; then, the co-cultured cells were sorted by fluorescence activated cell sorter (FACS), and the differentiation of co-cultured RAW264.7 cells was evaluated. The results showed that the differentiation potential of RAW264.7 cells was significantly inhibited after their co-culture with EPCs. Additionally, the expression of macrophage migration inhibitory factor (MIF) was up-regulated in RAW264.7 cells after co-culture. Moreover, the MIF inhibitor ISO-1 could rescue the formation of TRAP-positive multinuclear osteoclasts and the expression of osteoclastogenesis-associated genes in the co-cultured RAW264.7 cells. The present study demonstrates that EPCs can affect the differentiation of osteoclast precursors through the TNT-like structures formed across these two types of cells and might inform new therapeutic strategies for osteolytic diseases.
Collapse
|
17
|
Li X, Liu D, Li J, Yang S, Xu J, Yokota H, Zhang P. Wnt3a involved in the mechanical loading on improvement of bone remodeling and angiogenesis in a postmenopausal osteoporosis mouse model. FASEB J 2019; 33:8913-8924. [PMID: 31017804 DOI: 10.1096/fj.201802711r] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Osteoporosis is a major health problem, making bones fragile and susceptible to fracture. Previous works showed that mechanical loading stimulated bone formation and accelerated fracture healing. Focusing on the role of Wnt3a (wingless/integrated 3a), this study was aimed to assess effects of mechanical loading to the spine, using ovariectomized (OVX) mice as a model of osteoporosis. Two-week daily application of this novel loading (4 N, 10 Hz, 5 min/d) altered bone remodeling with an increase in Wnt3a. Spinal loading promoted osteoblast differentiation, endothelial progenitor cell migration, and tube formation and inhibited osteoclast formation, migration, and adhesion. A transient silencing of Wnt3a altered the observed loading effects. Spinal loading significantly increased bone mineral density, bone mineral content, and bone area per tissue area. The loaded OVX group showed a significant increase in the number of osteoblasts and reduction in osteoclast surface/bone surface. Though expression of osteoblastic genes was increased, the levels of osteoclastic genes were decreased by loading. Spinal loading elevated a microvascular volume as well as VEGF expression. Collectively, this study supports the notion that Wnt3a-mediated signaling involves in the effect of spinal loading on stimulating bone formation, inhibiting bone resorption, and promoting angiogenesis in OVX mice. It also suggests that Wnt3a might be a potential therapeutic target for osteoporosis treatment.-Li, X., Liu, D., Li, J., Yang, S., Xu, J., Yokota, H., Zhang, P. Wnt3a involved in the mechanical loading on improvement of bone remodeling and angiogenesis in a postmenopausal osteoporosis mouse model.
Collapse
Affiliation(s)
- Xinle Li
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.,Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin, China; and
| | - Daquan Liu
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.,Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin, China; and
| | - Jie Li
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
| | - Shuang Yang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
| | - Jinfeng Xu
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China
| | - Hiroki Yokota
- Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, Indiana, USA
| | - Ping Zhang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.,Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin, China; and.,Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, Indiana, USA
| |
Collapse
|
18
|
Howait M, Albassam A, Yamada C, Sasaki H, Bahammam L, Azuma MM, Cintra LTA, Satoskar AR, Yamada S, White R, Kawai T, Movila A. Elevated Expression of Macrophage Migration Inhibitory Factor Promotes Inflammatory Bone Resorption Induced in a Mouse Model of Periradicular Periodontitis. THE JOURNAL OF IMMUNOLOGY 2019; 202:2035-2043. [PMID: 30737274 DOI: 10.4049/jimmunol.1801161] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Accepted: 01/15/2019] [Indexed: 12/23/2022]
Abstract
Locally produced osteoclastogenic factor RANKL plays a critical role in the development of bone resorption in periradicular periodontitis. However, because RANKL is also required for healthy bone remodeling, it is plausible that a costimulatory molecule that upregulates RANKL production in inflammatory periradicular periodontitis may be involved in the pathogenic bone loss processes. We hypothesized that macrophage migration inhibitory factor (MIF) would play a role in upregulating the RANKL-mediated osteoclastogenesis in the periradicular lesion. In response to pulp exposure, the bone loss and level of MIF mRNA increased in the periradicular periodontitis, which peaked at 14 d, in conjunction with the upregulated expressions of mRNAs for RANKL, proinflammatory cytokines (TNF-α, IL-6, and IL-1β), chemokines (MCP-1 and SDF-1), and MIF's cognate receptors CXCR4 and CD74. Furthermore, expressions of those mRNAs were found significantly higher in wild-type mice compared with that of MIF-/- mice. In contrast, bacterial LPS elicited the production of MIF from ligament fibroblasts in vitro, which, in turn, enhanced their productions of RANKL and TNF-α. rMIF significantly upregulated the number of TRAP+ osteoclasts in vitro. Finally, periapical bone loss induced in wild-type mice were significantly diminished in MIF-/- mice. Altogether, the current study demonstrated that MIF appeared to function as a key costimulatory molecule to upregulate RANKL-mediated osteoclastogenesis, leading to the pathogenically augmented bone resorption in periradicular lesions. These data also suggest that the approach to neutralize MIF activity may lead to the development of a therapeutic regimen for the prevention of pathogenic bone loss in periradicular periodontitis.
Collapse
Affiliation(s)
- Mohammed Howait
- School of Dental Medicine, Harvard University, Boston, MA 02115.,Faculty of Dentistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia.,The Forsyth Institute, Cambridge, MA 02142
| | - Abdullah Albassam
- School of Dental Medicine, Harvard University, Boston, MA 02115.,Faculty of Dentistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia.,The Forsyth Institute, Cambridge, MA 02142
| | - Chiaki Yamada
- College of Dental Medicine, Nova Southeastern University, Ft. Lauderdale, FL 33324
| | - Hajime Sasaki
- School of Dental Medicine, Harvard University, Boston, MA 02115.,The Forsyth Institute, Cambridge, MA 02142.,School of Dentistry, University of Michigan, Ann Arbor, MI 48109
| | - Laila Bahammam
- Faculty of Dentistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Mariane Maffei Azuma
- The Forsyth Institute, Cambridge, MA 02142.,School of Dentistry, University of Michigan, Ann Arbor, MI 48109
| | | | - Abhay R Satoskar
- Department of Microbiology, The Ohio State University, Columbus, OH 43210; and
| | - Satoru Yamada
- Graduate School of Dentistry, Tohoku University, Tohoku, Sendai 980-8575, Japan
| | - Robert White
- School of Dental Medicine, Harvard University, Boston, MA 02115
| | - Toshihisa Kawai
- College of Dental Medicine, Nova Southeastern University, Ft. Lauderdale, FL 33324
| | - Alexandru Movila
- School of Dental Medicine, Harvard University, Boston, MA 02115; .,The Forsyth Institute, Cambridge, MA 02142.,College of Dental Medicine, Nova Southeastern University, Ft. Lauderdale, FL 33324
| |
Collapse
|
19
|
Hathaway-Schrader JD, Steinkamp HM, Chavez MB, Poulides NA, Kirkpatrick JE, Chew ME, Huang E, Alekseyenko AV, Aguirre JI, Novince CM. Antibiotic Perturbation of Gut Microbiota Dysregulates Osteoimmune Cross Talk in Postpubertal Skeletal Development. THE AMERICAN JOURNAL OF PATHOLOGY 2019; 189:370-390. [PMID: 30660331 DOI: 10.1016/j.ajpath.2018.10.017] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Revised: 09/01/2018] [Accepted: 10/16/2018] [Indexed: 12/17/2022]
Abstract
Commensal gut microbiota-host immune responses are experimentally delineated via gnotobiotic animal models or alternatively by antibiotic perturbation of gut microbiota. Osteoimmunology investigations in germ-free mice, revealing that gut microbiota immunomodulatory actions critically regulate physiologic skeletal development, highlight that antibiotic perturbation of gut microbiota may dysregulate normal osteoimmunological processes. We investigated the impact of antibiotic disruption of gut microbiota on osteoimmune response effects in postpubertal skeletal development. Sex-matched C57BL/6T mice were administered broad-spectrum antibiotics or vehicle-control from the age of 6 to 12 weeks. Antibiotic alterations in gut bacterial composition and skeletal morphology were sex dependent. Antibiotics did not influence osteoblastogenesis or endochondral bone formation, but notably enhanced osteoclastogenesis. Unchanged Tnf or Ccl3 expression in marrow and elevated tumor necrosis factor-α and chemokine (C-C motif) ligand 3 in serum indicated that the pro-osteoclastic effects of the antibiotics are driven by increased systemic inflammation. Antibiotic-induced broad changes in adaptive and innate immune cells in mesenteric lymph nodes and spleen demonstrated that the perturbation of gut microbiota drives a state of dysbiotic hyperimmune response at secondary lymphoid tissues draining local gut and systemic circulation. Antibiotics up-regulated the myeloid-derived suppressor cells, immature myeloid progenitor cells known for immunosuppressive properties in pathophysiologic inflammatory conditions. Myeloid-derived suppressor cell-mediated immunosuppression can be antigen specific. Therefore, antibiotic-induced broad suppression of major histocompatibility complex class II antigen presentation genes in bone marrow discerns that antibiotic perturbation of gut microbiota dysregulates critical osteoimmune cross talk.
Collapse
Affiliation(s)
- Jessica D Hathaway-Schrader
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina; Endocrinology Division, Department of Pediatrics, Medical University of South Carolina College of Medicine, Charleston, South Carolina
| | - Heidi M Steinkamp
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina; Division of Pediatric Dentistry, The Ohio State University College of Dentistry, Columbus, Ohio
| | - Michael B Chavez
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina; Division of Biosciences, The Ohio State University College of Dentistry, Columbus, Ohio
| | - Nicole A Poulides
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina; Endocrinology Division, Department of Pediatrics, Medical University of South Carolina College of Medicine, Charleston, South Carolina
| | - Joy E Kirkpatrick
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina
| | - Michael E Chew
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina
| | - Emily Huang
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina
| | - Alexander V Alekseyenko
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina; Department of Public Health Sciences, Medical University of South Carolina College of Medicine, Charleston, South Carolina
| | - Jose I Aguirre
- Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida
| | - Chad M Novince
- Department of Oral Health Sciences, Medical University of South Carolina College of Dental Medicine, Charleston, South Carolina; Endocrinology Division, Department of Pediatrics, Medical University of South Carolina College of Medicine, Charleston, South Carolina.
| |
Collapse
|
20
|
Lai CW, Chen HL, Tu MY, Lin WY, Röhrig T, Yang SH, Lan YW, Chong KY, Chen CM. A novel osteoporosis model with ascorbic acid deficiency in Akr1A1 gene knockout mice. Oncotarget 2018; 8:7357-7369. [PMID: 28060768 PMCID: PMC5352327 DOI: 10.18632/oncotarget.14458] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2016] [Accepted: 12/07/2016] [Indexed: 12/26/2022] Open
Abstract
The AKR1A1 protein is a member of the aldo-keto reductase superfamily that is responsible for the conversion of D-glucuronate to L-gulonate in the ascorbic acid (vitamin C) synthesis pathway. In a pCAG-eGFP transgenic mouse line that was produced by pronuclear microinjection, the integration of the transgene resulted in a 30-kb genomic DNA deletion, including the Akr1A1 gene, and thus caused the knockout (KO) of the Akr1A1 gene and targeting of the eGFP gene. The Akr1A1 KO mice (Akr1A1eGFP/eGFP) exhibited insufficient serum ascorbic acid levels, abnormal bone development and osteoporosis. Using micro-CT analysis, the results showed that the microarchitecture of the 12-week-old Akr1A1eGFP/eGFP mouse femur was shorter in length and exhibited less cortical bone thickness, enlargement of the bone marrow cavity and a complete loss of the trabecular bone in the distal femur. The femoral head and neck of the proximal femur also showed a severe loss of bone mass. Based on the decreased levels of serum osteocalcin and osteoblast activity in the Akr1A1eGFP/eGFP mice, the osteoporosis might be caused by impaired bone formation. In addition, administration of ascorbic acid to the Akr1A1eGFP/eGFP mice significantly prevented the condition of osteoporotic femurs and increased bone formation. Therefore, through ascorbic acid administration, the Akr1A1 KO mice exhibited controllable osteoporosis and may serve as a novel model for osteoporotic research.
Collapse
Affiliation(s)
- Cheng-Wei Lai
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.,Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan
| | - Hsiao-Ling Chen
- Department of Bioresources, Da-Yeh University, Changhua, Taiwan
| | - Min-Yu Tu
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.,Department of Orthopaedic Surgery, Taichung Armed Forces General Hospital, Taichung, Taiwan and National Defense Medical Center, Taipei, Taiwan.,Department of Biomedical Engineering, Hungkuang University, Taichung, Taiwan
| | - Wei-Yu Lin
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.,Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan
| | - Theresa Röhrig
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.,Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan
| | - Shang-Hsun Yang
- Department of Physiology and Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan
| | - Ying-Wei Lan
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.,Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
| | - Kowit-Yu Chong
- Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.,Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Tao-Yuan, Taiwan
| | - Chuan-Mu Chen
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.,Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.,Rong-Hsing Translational Medicine Center, and iEGG Center, National Chung Hsing University, Taichung, Taiwan
| |
Collapse
|
21
|
Amarasekara DS, Yun H, Kim S, Lee N, Kim H, Rho J. Regulation of Osteoclast Differentiation by Cytokine Networks. Immune Netw 2018; 18:e8. [PMID: 29503739 PMCID: PMC5833125 DOI: 10.4110/in.2018.18.e8] [Citation(s) in RCA: 294] [Impact Index Per Article: 49.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Revised: 02/02/2018] [Accepted: 02/03/2018] [Indexed: 12/20/2022] Open
Abstract
Cytokines play a pivotal role in maintaining bone homeostasis. Osteoclasts (OCs), the sole bone resorbing cells, are regulated by numerous cytokines. Macrophage colony-stimulating factor and receptor activator of NF-κB ligand play a central role in OC differentiation, which is also termed osteoclastogenesis. Osteoclastogenic cytokines, including tumor necrosis factor-α, IL-1, IL-6, IL-7, IL-8, IL-11, IL-15, IL-17, IL-23, and IL-34, promote OC differentiation, whereas anti-osteoclastogenic cytokines, including interferon (IFN)-α, IFN-β, IFN-γ, IL-3, IL-4, IL-10, IL-12, IL-27, and IL-33, downregulate OC differentiation. Therefore, dynamic regulation of osteoclastogenic and anti-osteoclastogenic cytokines is important in maintaining the balance between bone-resorbing OCs and bone-forming osteoblasts (OBs), which eventually affects bone integrity. This review outlines the osteoclastogenic and anti-osteoclastogenic properties of cytokines with regard to osteoimmunology, and summarizes our current understanding of the roles these cytokines play in osteoclastogenesis.
Collapse
Affiliation(s)
| | - Hyeongseok Yun
- Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea
| | - Sumi Kim
- Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea
| | - Nari Lee
- Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea
| | - Hyunjong Kim
- Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea
| | - Jaerang Rho
- Department of Microbiology and Molecular Biology, Chungnam National University, Daejeon 34134, Korea
| |
Collapse
|
22
|
Kim HS, Nam ST, Mun SH, Lee SK, Kim HW, Park YH, Kim B, Won KJ, Kim HR, Park YM, Kim HS, Beaven MA, Kim YM, Choi WS. DJ-1 controls bone homeostasis through the regulation of osteoclast differentiation. Nat Commun 2017; 8:1519. [PMID: 29142196 PMCID: PMC5688089 DOI: 10.1038/s41467-017-01527-y] [Citation(s) in RCA: 73] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Accepted: 09/25/2017] [Indexed: 11/09/2022] Open
Abstract
Receptor activator of NF-kB ligand (RANKL) generates intracellular reactive oxygen species (ROS), which increase RANKL-mediated signaling in osteoclast (OC) precursor bone marrow macrophages (BMMs). Here we show that a ROS scavenging protein DJ-1 negatively regulates RANKL-driven OC differentiation, also called osteoclastogenesis. DJ-1 ablation in mice leads to a decreased bone volume and an increase in OC numbers. In vitro, the activation of RANK-dependent signals is enhanced in DJ-1-deficient BMMs as compared to wild-type BMMs. DJ-1 suppresses the activation of both RANK-TRAF6 and RANK-FcRγ/Syk signaling pathways because of activation of Src homology region 2 domain-containing phosphatase-1, which is inhibited by ROS. Ablation of DJ-1 in mouse models of arthritis and RANKL-induced bone disease leads to an increase in the number of OCs, and exacerbation of bone damage. Overall, our results suggest that DJ-1 plays a role in bone homeostasis in normal physiology and in bone-associated pathology by negatively regulating osteoclastogenesis. Osteoclasts are involved in arthritis, and their differentiation depends on RANKL signaling. The author show that the ROS-scavenging protein DJ-1 negatively regulates RANKL signaling and that its ablation increases osteoclast numbers and exacerbates bone damage in mouse models of arthritis.
Collapse
Affiliation(s)
- Hyuk Soon Kim
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea
| | - Seung Taek Nam
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea
| | - Se Hwan Mun
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea.,Department of Medicine, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT, 06030, USA
| | - Sun-Kyeong Lee
- Department of Medicine, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT, 06030, USA
| | - Hyun Woo Kim
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea
| | - Young Hwan Park
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea
| | - Bokyung Kim
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea
| | - Kyung-Jong Won
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea
| | - Hae-Rim Kim
- Department of Rheumatology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea
| | - Yeong-Min Park
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea
| | - Hyung Sik Kim
- Department of Toxicology, School of Pharmacy, Sungkyunkwan University, Suwon, 440-746, Republic of Korea
| | - Michael A Beaven
- Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Young Mi Kim
- Department of Preventive Pharmacy, College of Pharmacy, Duksung Women's University, Seoul, 132-714, Republic of Korea
| | - Wahn Soo Choi
- Department of Immunology and Physiology, School of Medicine, Konkuk University, Chungju, 380-701, Republic of Korea.
| |
Collapse
|
23
|
Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J, Gracey E, Haroon N. Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis. Arthritis Rheumatol 2017; 69:1796-1806. [PMID: 28597514 DOI: 10.1002/art.40175] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Accepted: 06/06/2017] [Indexed: 12/17/2022]
Abstract
OBJECTIVE To investigate the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of ankylosing spondylitis (AS). METHODS Patients who met the modified New York criteria for AS were recruited for the study. Healthy volunteers, rheumatoid arthritis patients, and osteoarthritis patients were included as controls. Based on the annual rate of increase in modified Stoke AS Spine Score (mSASSS), AS patients were classified as progressors or nonprogressors. MIF levels in serum and synovial fluid were quantitated by enzyme-linked immunosorbent assay. Predictors of AS progression were evaluated using logistic regression analysis. Immunohistochemical analysis of ileal tissue was performed to identify MIF-producing cells. Flow cytometry was used to identify MIF-producing subsets, expression patterns of the MIF receptor (CD74), and MIF-induced tumor necrosis factor (TNF) production in the peripheral blood. MIF-induced mineralization of osteoblast cells (SaOS-2) was analyzed by alizarin red S staining, and Western blotting was used to quantify active β-catenin levels. RESULTS Baseline serum MIF levels were significantly elevated in AS patients compared to healthy controls and were found to independently predict AS progression. MIF levels were higher in the synovial fluid of AS patients, and MIF-producing macrophages and Paneth cells were enriched in their gut. MIF induced TNF production in monocytes, activated β-catenin in osteoblasts, and promoted the mineralization of osteoblasts. CONCLUSION Our findings indicate an unexplored pathogenic role of MIF in AS and a link between inflammation and new bone formation.
Collapse
Affiliation(s)
| | | | - Fanxing Zeng
- University Health Network and Krembil Research Institute, Toronto, Ontario, Canada
| | - Ismail Sari
- University Health Network and University of Toronto, Toronto, Ontario, Canada, and Dokuz Eylul University, Izmir, Turkey
| | | | - Janogini Muralitharan
- Krembil Research Institute, Toronto, Ontario, Canada, and McMaster University, Hamilton, Ontario, Canada
| | - Eric Gracey
- University Health Network and Krembil Research Institute, Toronto, Ontario, Canada
| | - Nigil Haroon
- University Health Network, Krembil Research Institute, and University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
24
|
Liu D, Zhang Y, Li X, Li J, Yang S, Xing X, Fan G, Yokota H, Zhang P. eIF2α signaling regulates ischemic osteonecrosis through endoplasmic reticulum stress. Sci Rep 2017; 7:5062. [PMID: 28698612 PMCID: PMC5505953 DOI: 10.1038/s41598-017-05488-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 05/15/2017] [Indexed: 12/25/2022] Open
Abstract
Osteonecrosis of the femoral head (ONFH) primarily results from ischemia/hypoxia to the femoral head, and one of the cellular manifestations is the endoplasmic reticulum (ER) stress. To understand possible linkage of ischemic osteonecrosis to the ER stress, a surgery-induced animal model was employed and salubrinal was administered to evaluate the role of ER stress. Salubrinal is a synthetic chemical that inhibits de-phosphorylation of eIF2α, and it can suppress cell death from the ER stress at a proper dose. The results indicated that the ER stress was associated with ONFH and salubrinal significantly improved ONFH-induced symptoms such as osteonecrosis, bone loss, reduction in vessel perfusion, and excessive osteoclastogenesis in the femoral head. Salubrinal also protected osteoblast development by upregulating the levels of ATF4, ALP and RUNX2, and it stimulated angiogenesis of endothelial cells through elevating ATF4 and VEGF. Collectively, the results support the notion that the ER stress is an important pathological outcome in the surgery-induced ONFH model, and salubrinal improves ONFH symptoms by enhancing angiogenesis and bone healing via suppressing the ER stress.
Collapse
Affiliation(s)
- Daquan Liu
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China
- Department of Pharmacology, Institute of Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin, 300100, China
- TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300457, China
| | - Yunlong Zhang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China
- School of Stomatology, Tianjin Medical University, Tianjin, 300070, China
| | - Xinle Li
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China
- TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300457, China
- Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin, 300070, China
| | - Jie Li
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China
| | - Shuang Yang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China
| | - Xiaoxue Xing
- State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China
| | - Guanwei Fan
- State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China
| | - Hiroki Yokota
- Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202, USA
| | - Ping Zhang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.
- TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300457, China.
- Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin, 300070, China.
- Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202, USA.
| |
Collapse
|
25
|
Yeon Won H, Hwan Mun S, Shin B, Lee SK. Contradictory Role of CD97 in Basal and Tumor Necrosis Factor-Induced Osteoclastogenesis In Vivo. Arthritis Rheumatol 2017; 68:1301-13. [PMID: 26663852 DOI: 10.1002/art.39538] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Accepted: 12/01/2015] [Indexed: 01/02/2023]
Abstract
OBJECTIVE CD97, a member of the 7-transmembrane epidermal growth factor family of adhesion G protein-coupled receptors, is expressed on various cell types. This study was undertaken to elucidate the functions of CD97 in bone and inflammation in an experimental mouse model, by examining the effect of CD97 on osteoclastogenesis in vitro, characterizing the skeletal phenotype of CD97-deficient (CD97-knockout [KO]) mice, and assessing the responses to tumor necrosis factor (TNF) treatment. METHODS Femoral tissue and bone marrow (BM)-derived cells from CD97-KO and wild-type (WT) mice were assessed using histomorphometric analyses, in vitro cultures, and reverse transcription-polymerase chain reaction. Serum cytokine and chemokine levels in the presence or absence of TNF challenge were analyzed by multiplex assay. RESULTS In cultures of mouse BM-derived macrophages in vitro, RANKL induced the expression of CD97. In vivo, the trabecular bone volume of the femurs of female CD97-KO mice was increased, and this was associated with a decrease in the number of osteoclasts. Compared to WT mice, CD97-KO mice had a reduced potential to form osteoclast-like cells in vitro. Furthermore, TNF treatment augmented the formation of osteoclasts in the calvaria of CD97-KO mice in vivo, by increasing the production of RANKL and other cytokines and chemokines and by reducing the production of osteoprotegerin by calvarial cells. CONCLUSION These findings demonstrate that CD97 is a positive regulator of osteoclast-like cell differentiation, a mechanism that influences bone homeostasis. However, the presence of CD97 may be essential to suppress the initial osteoclastogenesis that occurs in response to acute and local inflammatory stimuli.
Collapse
Affiliation(s)
| | | | - Bongjin Shin
- University of Connecticut Health Center, Farmington
| | | |
Collapse
|
26
|
Li J, Yang S, Li X, Liu D, Wang Z, Guo J, Tan N, Gao Z, Zhao X, Zhang J, Gou F, Yokota H, Zhang P. Role of endoplasmic reticulum stress in disuse osteoporosis. Bone 2017; 97:2-14. [PMID: 27989543 DOI: 10.1016/j.bone.2016.12.009] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Revised: 10/28/2016] [Accepted: 12/14/2016] [Indexed: 12/14/2022]
Abstract
Osteoporosis is a major skeletal disease with low bone mineral density, which leads to an increased risk of bone fracture. Salubrinal is a synthetic chemical that inhibits dephosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α) in response to endoplasmic reticulum (ER) stress. To understand possible linkage of osteoporosis to ER stress, we employed an unloading mouse model and examined the effects of salubrinal in the pathogenesis of disuse osteoporosis. The results presented several lines of evidence that osteoclastogenesis in the development of osteoporosis was associated with ER stress, and salubrinal suppressed unloading-induced bone loss. Compared to the age-matched control, unloaded mice reduced the trabecular bone area/total area (B.Ar/T.Ar) as well as the number of osteoblasts, and they increased the osteoclasts number on the trabecular bone surface in a time-dependent way. Unloading-induced disuse osteoporosis significantly increased the expression of Bip, p-eIF2α and ATF4 in short-term within 6h of tail suspension, but time-dependent decreased in HU2d to HU14d. Furthermore, a significant correlation of ER stress with the differentiation of osteoblasts and osteoclasts was observed. Administration of salubrinal suppressed the unloading-induced decrease in bone mineral density, B.Ar/T.Ar and mature osteoclast formation. Salubrinal also increased the colony-forming unit-fibroblasts and colony-forming unit-osteoblasts. It reduced the formation of mature osteoclasts, suppressed their migration and adhesion, and increased the expression of Bip, p-eIF2α and ATF4. Electron microscopy showed that rough endoplasmic reticulum expansion and a decreased number of ribosomes on ER membrane were observed in osteoblast of unloading mice, and the abnormal ER expansion was significantly improved by salubrinal treatment. A TUNEL assay together with CCAAT/enhancer binding protein homologous protein (CHOP) expression indicated that ER stress-induced osteoblast apoptosis was rescued by salubrinal. Collectively, the results support the notion that ER stress plays a key role in the pathogenesis of disuse osteoporosis, and salubrinal attenuates unloading-induced bone loss by altering proliferation and differentiation of osteoblasts and osteoclasts via eIF2α signaling.
Collapse
Affiliation(s)
- Jie Li
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300457, China
| | - Shuang Yang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300457, China
| | - Xinle Li
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300457, China; Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin 300070, China
| | - Daquan Liu
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300457, China; Department of Pharmacology, Institute of Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin 300100, China
| | - Zhaonan Wang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Jialu Guo
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Nian Tan
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Zhe Gao
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Xiaoyu Zhao
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Jiuguo Zhang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Fanglin Gou
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Hiroki Yokota
- Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, IN 46202, USA
| | - Ping Zhang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300457, China; Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin 300070, China; Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, IN 46202, USA.
| |
Collapse
|
27
|
Du E, McAllister P, Venna VR, Xiao L. Clinically Relevant Concentrations of Ketamine Inhibit Osteoclast Formation In Vitro in Mouse Bone Marrow Cultures. J Cell Biochem 2016; 118:914-923. [PMID: 27775174 DOI: 10.1002/jcb.25772] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Accepted: 10/21/2016] [Indexed: 11/09/2022]
Abstract
Ketamine has been used safely in clinics for decades for analgesia and anesthesia. It is increasingly popular in clinical practice due to its new uses and importance for emergency procedures. It is known that ketamine is sequestered in the bone marrow and the major receptors for ketamine, noncompetitive N-methyl-d-aspartate receptors (NMDARs), are expressed in osteoclasts (OCs) and osteoblasts. However, the impact of ketamine on OCs or osteoblasts is unknown. In this study, we investigated the effects of ketamine on osteoclastogenesis and regulation of NMDARs expression in vitro. Bone marrows (BMs) or bone marrow macrophages (BMMs) were cultured in the presence of macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) with or without ketamine for up to 6 days. OC formation peaked at day 5. On day 5 of culture, ketamine inhibited OC formation from both BM and BMM cultures at clinically relevant concentrations (3-200 µM). Ketamine inhibited RANKL-induced expression of nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1) in BMM cultures. Inhibition of ketamine on RANKL-induced osteoclastogenesis is associated with down-regulation of NMDARs. In addition, ketamine significantly inhibited the M-CSF induced migration of BMMs, inhibited cell fusion and significantly increased mature OC apoptosis. We conclude that clinically relevant concentrations of ketamine inhibit OC formation in both BM and BMM cultures in vitro through inhibiting migration and fusion process and enhancing mature OC apoptosis. It is likely that ketamine regulates osteoclastogenesis, at least in part, via its effects on NMDAR expression. J. Cell. Biochem. 118: 914-923, 2017. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Erxia Du
- Department of Medicine, UConn Health, Farmington, Connecticut
| | - Patrick McAllister
- Department of Medicine, UConn Health, Farmington, Connecticut.,Department of Biology, UConn Health, Farmington, Connecticut
| | - Venugopal Reddy Venna
- Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas
| | - Liping Xiao
- Department of Medicine, UConn Health, Farmington, Connecticut.,Department of Psychiatry, UConn Health, Farmington, Connecticut
| |
Collapse
|
28
|
Movila A, Ishii T, Albassam A, Wisitrasameewong W, Howait M, Yamaguchi T, Ruiz-Torruella M, Bahammam L, Nishimura K, Van Dyke T, Kawai T. Macrophage Migration Inhibitory Factor (MIF) Supports Homing of Osteoclast Precursors to Peripheral Osteolytic Lesions. J Bone Miner Res 2016; 31:1688-700. [PMID: 27082509 PMCID: PMC5010512 DOI: 10.1002/jbmr.2854] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 03/28/2016] [Accepted: 04/12/2016] [Indexed: 12/11/2022]
Abstract
By binding to its chemokine receptor CXCR4 on osteoclast precursor cells (OCPs), it is well known that stromal cell-derived factor-1 (SDF-1) promotes the chemotactic recruitment of circulating OCPs to the homeostatic bone remodeling site. However, the engagement of circulating OCPs in pathogenic bone resorption remains to be elucidated. The present study investigated a possible chemoattractant role of macrophage migration inhibitory factor (MIF), another ligand for C-X-C chemokine receptor type 4 (CXCR4), in the recruitment of circulating OCPs to the bone lytic lesion. To accomplish this, we used Csf1r-eGFP-knock-in (KI) mice to establish an animal model of polymethylmethacrylate (PMMA) particle-induced calvarial osteolysis. In the circulating Csf1r-eGFP+ cells of healthy Csf1r-eGFP-KI mice, Csf1r+/CD11b+ cells showed a greater degree of RANKL-induced osteoclastogenesis compared to a subset of Csf1r+/RANK+ cells in vitro. Therefore, Csf1r-eGFP+/CD11b+ cells were targeted as functionally relevant OCPs in the present study. Although expression of the two cognate receptors for MIF, CXCR2 and CXCR4, was elevated on Csf1r+/CD11b+ cells, transmigration of OCPs toward recombinant MIF in vitro was facilitated by ligation with CXCR4, but not CXCR2. Meanwhile, the level of PMMA-induced bone resorption in calvaria was markedly greater in wild-type (WT) mice compared to that detected in MIF-knockout (KO) mice. Interestingly, in contrast to the elevated MIF, diminished SDF-1 was detected in a particle-induced bone lytic lesion of WT mice in conjunction with an increased number of infiltrating CXCR4+ OCPs. However, such diminished SDF-1 was not found in the PMMA-injected calvaria of MIF-KO mice. Furthermore, stimulation of osteoblasts with MIF in vitro suppressed their production of SDF-1, suggesting that MIF can downmodulate SDF-1 production in bone tissue. Systemically administered anti-MIF neutralizing monoclonal antibody (mAb) inhibited the homing of CXCR4+ OCPs, as well as bone resorption, in the PMMA-injected calvaria, while increasing locally produced SDF-1. Collectively, these data suggest that locally produced MIF in the inflammatory bone lytic site is engaged in the chemoattraction of circulating CXCR4+ OCPs. © 2016 American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Alexandru Movila
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA
| | - Takenobu Ishii
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA.,Department of Orthodontics, Tokyo Dental College, Tokyo, Japan
| | - Abdullah Albassam
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA.,School of Dental Medicine, Harvard University, Boston, MA, USA.,Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Wichaya Wisitrasameewong
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA.,School of Dental Medicine, Harvard University, Boston, MA, USA.,Department of Periodontology, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand
| | - Mohammed Howait
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA.,Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Tsuguno Yamaguchi
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA.,Research and Development Headquarters, LION Corporation, Kanagawa, Japan
| | | | - Laila Bahammam
- Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Kazuaki Nishimura
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA.,Graduate School of Dentistry, Tohoku University, Sendai, Japan
| | - Thomas Van Dyke
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA
| | - Toshihisa Kawai
- Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, USA.,School of Dental Medicine, Harvard University, Boston, MA, USA
| |
Collapse
|
29
|
Ahn SH, Park SY, Baek JE, Lee SY, Baek WY, Lee SY, Lee YS, Yoo HJ, Kim H, Lee SH, Im DS, Lee SK, Kim BJ, Koh JM. Free Fatty Acid Receptor 4 (GPR120) Stimulates Bone Formation and Suppresses Bone Resorption in the Presence of Elevated n-3 Fatty Acid Levels. Endocrinology 2016; 157:2621-35. [PMID: 27145004 DOI: 10.1210/en.2015-1855] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Free fatty acid receptor 4 (FFA4) has been reported to be a receptor for n-3 fatty acids (FAs). Although n-3 FAs are beneficial for bone health, a role of FFA4 in bone metabolism has been rarely investigated. We noted that FFA4 was more abundantly expressed in both mature osteoclasts and osteoblasts than their respective precursors and that it was activated by docosahexaenoic acid. FFA4 knockout (Ffar4(-/-)) and wild-type mice exhibited similar bone masses when fed a normal diet. Because fat-1 transgenic (fat-1(Tg+)) mice endogenously converting n-6 to n-3 FAs contain high n-3 FA levels, we crossed Ffar4(-/-) and fat-1(Tg+) mice over two generations to generate four genotypes of mice littermates: Ffar4(+/+);fat-1(Tg-), Ffar4(+/+);fat-1(Tg+), Ffar4(-/-);fat-1(Tg-), and Ffar4(-/-);fat-1(Tg+). Female and male littermates were included in ovariectomy- and high-fat diet-induced bone loss models, respectively. Female fat-1(Tg+) mice decreased bone loss after ovariectomy both by promoting osteoblastic bone formation and inhibiting osteoclastic bone resorption than their wild-type littermates, only when they had the Ffar4(+/+) background, but not the Ffar4(-/-) background. In a high-fat diet-fed model, male fat-1(Tg+) mice had higher bone mass resulting from stimulated bone formation and reduced bone resorption than their wild-type littermates, only when they had the Ffar4(+/+) background, but not the Ffar4(-/-) background. In vitro studies supported the role of FFA4 as n-3 FA receptor in bone metabolism. In conclusion, FFA4 is a dual-acting factor that increases osteoblastic bone formation and decreases osteoclastic bone resorption, suggesting that it may be an ideal target for modulating metabolic bone diseases.
Collapse
Affiliation(s)
- Seong Hee Ahn
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Sook-Young Park
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Ji-Eun Baek
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Su-Youn Lee
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Wook-Young Baek
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Sun-Young Lee
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Young-Sun Lee
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Hyun Ju Yoo
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Hyeonmok Kim
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Seung Hun Lee
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Dong-Soon Im
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Sun-Kyeong Lee
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Beom-Jun Kim
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| | - Jung-Min Koh
- Department of Endocrinology and Metabolism (S.H.A.), Inha University Hospital, Inha University School of Medicine, Incheon 402-751, South Korea; Asan Institute for Life Sciences (S.-Y.P., J.-E.B., S.-Youn.L., W.-.Y.B., S.-Young.L., Y.-S.L.) and Biomedical Research Center (H.J.Y.) and Division of Endocrinology and Metabolism (H.K., S.H.L., B.-J.K., J.-M.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea; Molecular Inflammation Research Center for Aging Intervention and College of Pharmacy (D.-S.I.), Pusan National University, Busan 609-735, South Korea; and UConn Center on Aging (S.-K.L.), University of Connecticut Health Center, Farmington, Connecticut 06030-1601
| |
Collapse
|
30
|
Przybyl L, Haase N, Golic M, Rugor J, Solano ME, Arck PC, Gauster M, Huppertz B, Emontzpohl C, Stoppe C, Bernhagen J, Leng L, Bucala R, Schulz H, Heuser A, Weedon-Fekjær MS, Johnsen GM, Peetz D, Luft FC, Staff AC, Müller DN, Dechend R, Herse F. CD74-Downregulation of Placental Macrophage-Trophoblastic Interactions in Preeclampsia. Circ Res 2016; 119:55-68. [PMID: 27199465 DOI: 10.1161/circresaha.116.308304] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 05/19/2016] [Indexed: 01/28/2023]
Abstract
RATIONALE We hypothesized that cluster of differentiation 74 (CD74) downregulation on placental macrophages, leading to altered macrophage-trophoblast interaction, is involved in preeclampsia. OBJECTIVE Preeclamptic pregnancies feature hypertension, proteinuria, and placental anomalies. Feto-placental macrophages regulate villous trophoblast differentiation during placental development. Disturbance of this well-balanced regulation can lead to pathological pregnancies. METHODS AND RESULTS We performed whole-genome expression analysis of placental tissue. CD74 was one of the most downregulated genes in placentas from preeclamptic women. By reverse transcriptase-polymerase chain reaction, we confirmed this finding in early-onset (<34 gestational week, n=26) and late-onset (≥34 gestational week, n=24) samples from preeclamptic women, compared with healthy pregnant controls (n=28). CD74 protein levels were analyzed by Western blot and flow cytometry. We identified placental macrophages to express CD74 by immunofluorescence, flow cytometry, and RT-PCR. CD74-positive macrophages were significantly reduced in preeclamptic placentas compared with controls. CD74-silenced macrophages showed that the adhesion molecules ALCAM, ICAM4, and Syndecan-2, as well as macrophage adhesion to trophoblasts were diminished. Naive and activated macrophages lacking CD74 showed a shift toward a proinflammatory signature with an increased secretion of tumor necrosis factor-α, chemokine (C-C motif) ligand 5, and monocyte chemotactic protein-1, when cocultured with trophoblasts compared with control macrophages. Trophoblasts stimulated by these factors express more CYP2J2, sFlt1, TNFα, and IL-8. CD74-knockout mice showed disturbed placental morphology, reduced junctional zone, smaller placentas, and impaired spiral artery remodeling with fetal growth restriction. CONCLUSIONS CD74 downregulation in placental macrophages is present in preeclampsia. CD74 downregulation leads to altered macrophage activation toward a proinflammatory signature and a disturbed crosstalk with trophoblasts.
Collapse
Affiliation(s)
- Lukasz Przybyl
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Nadine Haase
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Michaela Golic
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Julianna Rugor
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Maria Emilia Solano
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Petra Clara Arck
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Martin Gauster
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Berthold Huppertz
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Christoph Emontzpohl
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Christian Stoppe
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Jürgen Bernhagen
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Lin Leng
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Richard Bucala
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Herbert Schulz
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Arnd Heuser
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - M Susanne Weedon-Fekjær
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Guro M Johnsen
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Dirk Peetz
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Friedrich C Luft
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Anne Cathrine Staff
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Dominik N Müller
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Ralf Dechend
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.)
| | - Florian Herse
- From the Experimental and Clinical Research Center, A Joint Cooperation Between the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité Medical Faculty, Berlin, Germany (L.P., N.H., M. Golic, J.R., F.C.L., D.N.M., R.D., F.H.); Berlin Institute of Health (BIH), Berlin, Germany (L.P., N.H., M. Golic, J.R., D.N.M., R.D., F.H.); Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (N.H., H.S., A.H., F.C.L., D.N.M., F.H.); Departments of Obstetrics, Gynecology, and Senology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany (M. Golic); Department of Obstetrics and Fetal Medicine, Laboratory for Experimental Feto-Maternal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M.E.S., P.C.A.); Institute of Cell Biology, Histology, and Embryology, Medical University of Graz, Graz, Austria (M. Gauster, B.H.); Institute of Biochemistry and Molecular Cell Biology (C.E., C.S., J.B.) and Department of Anesthesiology (C.S.), RWTH Aachen University, Aachen, Germany; Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany (J.B.); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (J.B.); Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (L.L., R.B.); Cologne Center for Genomics (CCG), University of Cologne, Köln, Germany (H.S.); Departments of Obstetrics and Gynaecology, Oslo University Hospital, Ulleval, Norway (M.S.W.-F., G.M.J., A.C.S.); University of Oslo, Oslo, Norway (M.S.W.-F., G.M.J., A.C.S.); and HELIOS-Klinikum, Berlin, Germany (D.P., R.D.).
| |
Collapse
|
31
|
Liu D, Li X, Li J, Yang J, Yokota H, Zhang P. Knee loading protects against osteonecrosis of the femoral head by enhancing vessel remodeling and bone healing. Bone 2015; 81:620-631. [PMID: 26416150 PMCID: PMC4641018 DOI: 10.1016/j.bone.2015.09.012] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Revised: 08/27/2015] [Accepted: 09/24/2015] [Indexed: 01/13/2023]
Abstract
Osteonecrosis of the femoral head is a serious orthopedic problem. Moderate loads with knee loading promote bone formation, but their effects on osteonecrosis have not been investigated. Using a rat model, we examined a hypothesis that knee loading enhances vessel remodeling and bone healing through the modulation of the fate of bone marrow-derived cells. In this study, osteonecrosis was induced by transecting the ligamentum teres followed by a tight ligature around the femoral neck. For knee loading, 5 N loads were laterally applied to the knee at 15 Hz for 5 min/day for 5 weeks. Changes in bone mineral density (BMD) and bone mineral content (BMC) of the femur were measured by pDEXA, and ink infusion was performed to evaluate vessel remodeling. Femoral heads were harvested for histomorphometry, and bone marrow-derived cells were isolated to examine osteoclast development and osteoblast differentiation. The results showed that osteonecrosis significantly induced bone loss, and knee loading stimulated both vessel remodeling and bone healing. The osteonecrosis group exhibited the lowest trabecular BV/TV (p b 0.001) in the femoral head, and lowest femoral BMD and BMC (both p b 0.01). However, knee loading increased trabecular BV/TV (p b 0.05) as well as BMD (pb 0.05) and BMC (p b 0.01). Osteonecrosis decreased the vessel volume (pb 0.001), vessel number (pb 0.001) and VEGF expression (p b 0.01), and knee loading increased them (pb 0.001, pb 0.001 and p b 0.01). Osteonecrosis activated osteoclast development, and knee loading reduced its formation, migration, adhesion and the level of “pit” formation (pb 0.001, pb 0.01, pb 0.001 and pb 0.001). Furthermore, knee loading significantly increased osteoblast differentiation and CFU-F (both p b 0.001). A significantly positive correlation was observed between vessel remodeling and bone healing (both p b 0.01). These results indicate that knee loading could be effective in repair osteonecrosis of the femoral head in a rat model. This effect might be attributed to promoting vessel remodeling, suppressing osteoclast development, and increasing osteoblast and fibroblast differentiation. In summary, the current study suggests that knee loading might potentially be employed as a non-invasive therapy for osteonecrosis of the femoral head.
Collapse
Affiliation(s)
- Daquan Liu
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; Department of Pharmacology, Institute of Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin 300100, China
| | - Xinle Li
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Jie Li
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Jing Yang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
| | - Hiroki Yokota
- Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, IN 46202, USA
| | - Ping Zhang
- Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, IN 46202, USA.
| |
Collapse
|
32
|
Canalis E, Schilling L, Yee SP, Lee SK, Zanotti S. Hajdu Cheney Mouse Mutants Exhibit Osteopenia, Increased Osteoclastogenesis, and Bone Resorption. J Biol Chem 2015; 291:1538-1551. [PMID: 26627824 DOI: 10.1074/jbc.m115.685453] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Indexed: 11/06/2022] Open
Abstract
Notch receptors are determinants of cell fate and function and play a central role in skeletal development and bone remodeling. Hajdu Cheney syndrome, a disease characterized by osteoporosis and fractures, is associated with NOTCH2 mutations resulting in a truncated stable protein and gain-of-function. We created a mouse model reproducing the Hajdu Cheney syndrome by introducing a 6955C→T mutation in the Notch2 locus leading to a Q2319X change at the amino acid level. Notch2(Q2319X) heterozygous mutants were smaller and had shorter femurs than controls; and at 1 month of age they exhibited cancellous and cortical bone osteopenia. As the mice matured, cancellous bone volume was restored partially in male but not female mice, whereas cortical osteopenia persisted in both sexes. Cancellous bone histomorphometry revealed an increased number of osteoclasts and bone resorption, without a decrease in osteoblast number or bone formation. Osteoblast differentiation and function were not affected in Notch2(Q2319X) cells. The pre-osteoclast cell pool, osteoclast differentiation, and bone resorption in response to receptor activator of nuclear factor κB ligand in vitro were increased in Notch2(Q2319X) mutants. These effects were suppressed by the γ-secretase inhibitor LY450139. In conclusion, Notch2(Q2319X) mice exhibit cancellous and cortical bone osteopenia, enhanced osteoclastogenesis, and increased bone resorption.
Collapse
Affiliation(s)
| | | | - Siu-Pok Yee
- Cell Biology, Genetics, and; Genome Sciences Biology
| | - Sun-Kyeong Lee
- Medicine,; Center on Aging, University of Connecticut Health Center, Farmington, Connecticut 06030
| | | |
Collapse
|
33
|
Ahn SH, Lee SY, Baek JE, Lee SY, Park SY, Lee YS, Kim H, Kim BJ, Lee SH, Koh JM. Psychosine inhibits osteoclastogenesis and bone resorption via G protein-coupled receptor 65. J Endocrinol Invest 2015; 38:891-9. [PMID: 25841894 DOI: 10.1007/s40618-015-0276-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 03/17/2015] [Indexed: 01/20/2023]
Abstract
BACKGROUND It was recently reported that G protein-coupled receptor 65 (GPR65) suppresses ovariectomy-induced bone loss. AIM The present study investigated the role of the lysosphingolipid psychosine, a GPR65 ligand, on osteoclastic differentiation and bone resorption. METHODS Osteoclasts were differentiated from mouse bone marrow macrophages. Tartrate-resistant acid phosphatase-positive multinucleated cells were considered to be osteoclasts, and the resorption area was measured by incubating the cells on dentine discs. The expression levels of osteoclast differentiation markers were assessed by qRT-PCR. GPR65 siRNA and its scrambled siRNA were transfected with lipofectamine. Intracellular cyclic adenosine monophosphate (cAMP) levels were assessed using a direct enzyme immunoassay. RESULTS Psychosine inhibited osteoclastogenesis and in vitro bone resorption without any significant effect on the viability of pre-osteoclasts, decreased the expression of osteoclast differentiation markers significantly, and increased intracellular cAMP levels. The knockdown of GPR65 by its siRNA restored osteoclastogenesis and decreased cAMP levels in the presence of psychosine. CONCLUSION Psychosine inhibits osteoclastogenesis by increasing intracellular cAMP levels via GPR65.
Collapse
Affiliation(s)
- S H Ahn
- Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Poongnap-2Dong, Songpa-Gu, Seoul, 138-736, South Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle-Rowson G, Bucala R, Xu J, Quinn JMW, Morand EF. Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. Cytokine 2015; 72:135-45. [PMID: 25647268 DOI: 10.1016/j.cyto.2014.11.015] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2014] [Revised: 10/27/2014] [Accepted: 11/16/2014] [Indexed: 01/21/2023]
Abstract
Macrophage migration inhibitory factor (MIF) enhances activation of leukocytes, endothelial cells and fibroblast-like synoviocytes (FLS), thereby contributing to the pathogenesis of rheumatoid arthritis (RA). A MIF promoter polymorphism in RA patients resulted in higher serum MIF concentration and worsens bone erosion; controversially current literature reported an inhibitory role of MIF in osteoclast formation. The controversial suggested that the precise role of MIF and its putative receptor CD74 in osteoclastogenesis and RA bone erosion, mediated by locally formed osteoclasts in response to receptor activator of NF-κB ligand (RANKL), is unclear. We reported that in an in vivo K/BxN serum transfer arthritis, reduced clinical and histological arthritis in MIF(-/-) and CD74(-/-) mice were accompanied by a virtual absence of osteoclasts at the synovium-bone interface and reduced osteoclast-related gene expression. Furthermore, in vitro osteoclast formation and osteoclast-related gene expression were significantly reduced in MIF(-/-) cells via decreasing RANKL-induced phosphorylation of NF-κB-p65 and ERK1/2. This was supported by a similar reduction of osteoclastogenesis observed in CD74(-/-) cells. Furthermore, a MIF blockade reduced RANKL-induced osteoclastogenesis via deregulating RANKL-mediated NF-κB and NFATc1 transcription factor activation. These data indicate that MIF and CD74 facilitate RANKL-induced osteoclastogenesis, and suggest that MIF contributes directly to bone erosion, as well as inflammation, in RA.
Collapse
Affiliation(s)
- Ran Gu
- Centre for Inflammatory Disease, Monash University, Clayton, Australia
| | - Leilani L Santos
- Centre for Inflammatory Disease, Monash University, Clayton, Australia
| | - Devi Ngo
- Centre for Inflammatory Disease, Monash University, Clayton, Australia
| | - HuaPeng Fan
- Centre for Inflammatory Disease, Monash University, Clayton, Australia
| | | | | | - Richard Bucala
- Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511, USA
| | - Jiake Xu
- School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley, Australia
| | - Julian M W Quinn
- Prince Henry's Institute, Clayton, Australia; Dept of Biochemistry and Molecular Biology, Monash University, Clayton, Australia
| | - Eric F Morand
- Centre for Inflammatory Disease, Monash University, Clayton, Australia.
| |
Collapse
|
35
|
Mun SH, Oh D, Lee SK. Macrophage migration inhibitory factor down-regulates the RANKL-RANK signaling pathway by activating Lyn tyrosine kinase in mouse models. Arthritis Rheumatol 2014; 66:2482-93. [PMID: 24891319 PMCID: PMC4146704 DOI: 10.1002/art.38723] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2013] [Accepted: 05/20/2014] [Indexed: 01/06/2023]
Abstract
OBJECTIVE Macrophage migration inhibitory factor (MIF) is an important modulator of innate and adaptive immunity as well as local inflammatory responses. We previously reported that MIF down-regulated osteoclastogenesis through a mechanism that requires CD74. The aim of the current study was to examine whether MIF modulates osteoclastogenesis through Lyn phosphorylation, and whether down-regulation of RANKL-mediated signaling requires the association of CD74, CD44, and Lyn. METHODS CD74-knockout (CD74-KO), CD44-KO, and Lyn-KO mouse models were used to investigate whether Lyn requires these receptors and coreceptors. The effects of MIF on osteoclastogenesis were assessed using Western blot analysis, small interfering RNA (siRNA)-targeted down-regulation of Lyn, Lyn-KO mice, and real-time imaging of Lyn molecules to surface proteins. RESULTS MIF treatment induced Lyn expression, and MIF down-regulated RANKL-induced activator protein 1 (AP-1) and the Syk/phospholipase Cγ cascade during osteoclastogenesis through activated Lyn tyrosine kinase. The results of immunoprecipitation studies revealed that MIF receptors associated with Lyn in response to MIF treatment. Studies using Lyn-specific siRNA and Lyn-KO mice confirmed our findings. CONCLUSION Our findings indicate that the tyrosine kinase Lyn is activated when MIF binds to its receptor CD74 and its coreceptor CD44 and, in turn, down-regulates the RANKL-mediated signaling cascade by suppressing NF-ATc1 protein expression through down-regulation of AP-1 and calcium signaling components.
Collapse
Affiliation(s)
- Se Hwan Mun
- UCONN Center on Aging, University of Connecticut Health Center, Farmington, CT 06030
| | - Dongmyung Oh
- Center for Cell Analysis and Modeling, University of Connecticut Health Center, Farmington, CT 06030
| | - Sun-Kyeong Lee
- UCONN Center on Aging, University of Connecticut Health Center, Farmington, CT 06030
| |
Collapse
|
36
|
Yokota H, Hamamura K, Chen A, Dodge TR, Tanjung N, Abedinpoor A, Zhang P. Effects of salubrinal on development of osteoclasts and osteoblasts from bone marrow-derived cells. BMC Musculoskelet Disord 2013; 14:197. [PMID: 23816340 PMCID: PMC3711788 DOI: 10.1186/1471-2474-14-197] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Accepted: 06/14/2013] [Indexed: 11/26/2022] Open
Abstract
Background Osteoporosis is a skeletal disease leading to an increased risk of bone fracture. Using a mouse osteoporosis model induced by administration of a receptor activator of nuclear factor kappa-B ligand (RANKL), salubrinal was recently reported as a potential therapeutic agent. To evaluate the role of salubrinal in cellular fates as well as migratory and adhesive functions of osteoclast/osteoblast precursors, we examined the development of primary bone marrow-derived cells in the presence and absence of salubrinal. We addressed a question: are salubrinal’s actions more potent to the cells isolated from the osteoporotic mice than those isolated from the control mice? Methods Using the RANKL-injected and control mice, bone marrow-derived cells were harvested. Osteoclastogenesis was induced by macrophage-colony stimulating factor and RANKL, while osteoblastogenesis was driven by dexamethasone, ascorbic acid, and β-glycerophosphate. Results The results revealed that salubrinal suppressed the numbers of colony forming-unit (CFU)-granulocyte/macrophages and CFU-macrophages, as well as formation of mature osteoclasts in a dosage-dependent manner. Salubrinal also suppressed migration and adhesion of pre-osteoclasts and increased the number of CFU-osteoblasts. Salubrinal was more effective in exerting its effects in the cells isolated from the RANKL-injected mice than the control. Consistent with cellular fates and functions, salubrinal reduced the expression of nuclear factor of activated T cells c1 (NFATc1) as well as tartrate-resistant acid phosphatase. Conclusions The results support the notion that salubrinal exhibits significant inhibition of osteoclastogenesis as well as stimulation of osteoblastogenesis in bone marrow-derived cells, and its efficacy is enhanced in the cells harvested from the osteoporotic bone samples.
Collapse
Affiliation(s)
- Hiroki Yokota
- Department of Biomedical Engineering, Indiana University-Purdue University Indianapolis, 723 West Michigan Street, SL220, Indianapolis, IN 46202, USA.
| | | | | | | | | | | | | |
Collapse
|